Despite intense research focus the prognosis for patients with glioblastoma (GBM) remains poor. Median survival with maximal intervention comprising surgical resection, radiotherapy and systemic chemotherapy is reported to be less than 15 months, and only a proportion of patients are suitable for this aggressive treatment strategy [1].The diffuse and infiltrative nature of GBM confers a number of challenges to effective treatment. Traditionally, cyto-reductive surgery has been targeted to the areas of macroscopic abnormality on MRI scans, guided by the operating microscope and limited by the eloquence of surrounding brain structures.
展开▼
